JAK2/IDH-mutant–driven myeloproliferative neoplasm is sensitive to combined targeted inhibition

Document Details

Document Type
Pub Defense Publication
Publication Date
Jan 22, 2018
Source ID
10.1172/jci94516

Entities

People

  • Alan H. Shih
  • Allison N Lau
  • Amritha Varshini Hanasoge Somasundara
  • Andrew M. Intlekofer
  • Anna Sophia Mckenney
  • April Chiu
  • Barbara Spitzer
  • Craig. B. Thompson
  • Efthymia Papalexi
  • Elizaveta Freinkman
  • Esra A Akbay
  • Franck T. Rapaport
  • Jihae Ahn
  • Julie Teruya-feldstein
  • Kaitlyn Shank
  • Katharine Yen
  • Kwok-kin Wong
  • Matthew G Vander Heiden
  • Minal A. Patel
  • Mya Steadman
  • Raajit Rampal
  • Raj Nagaraja
  • Ross L Levine

Organizations

  • Damon Runyon Cancer Research Foundation
  • Howard Hughes Medical Institute
  • Leukemia & Lymphoma Society
  • National Cancer Institute
  • National Institute of General Medical Sciences
  • National Institutes of Health
  • United States Department of Defense